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Huntington’s disease (HD) is an incurable neurodegenerative disease characterized
by the triad of chorea, cognitive dysfunction and psychiatric disturbances. Since the
discovery of the HD gene, the pathogenesis has been outlined, but to date a cure has not
been found. Disease modifying therapies are needed desperately to improve function,
alleviate suffering, and provide hope for symptomatic patients. Deep brain stimulation
(DBS), a proven therapy for managing the symptoms of some neurodegenerative
movement disorders, including Parkinson’s disease, has been reported as a palliative
treatment in select cases of HD with debilitating chorea with variable success. New
insights into the mechanism of action of DBS suggest it may have the potential to
circumvent other manifestations of HD including cognitive deterioration. Furthermore,
because DBS is already widely used, reversible, and has a risk profile that is relatively
low, new studies can be initiated. In this article we contend that new clinical trials be
considered to test the effects of DBS for HD.
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Preserving Cortico-Striatal Function: Deep Brain Stimulation in
Huntington’s Disease
Few conditions in medicine present patients and their families the challenges of Huntington’s
disease (HD). Because it is a heritable disease, the majority of individuals at risk are exposed to a
turbulent environment with a parent diagnosed with HD and faced with the reality of suffering a
similar fate. At-risk patients have the option to learn if they have the disease and thenmust confront
the sad truth that the disease will end in neurologic disability and premature death. For those who
elect not to be tested, the specter of developing symptomatic HD still looms large. This in part
contributes to the increased risk of suicide during early stages and engenders fear and desperation
that perpetuates itself with time as families search for answers (Meiser and Dunn, 2000). This
psychological burden, coupled with the absence of any promising interventions, contributes to
low predictive testing rates and the potential to adopt overly optimistic beliefs about one’s future,
which at times may have undesirable consequences from a medical or economic standpoint (Oster
et al., 2013).
It is estimated that 30,000 individuals in the United States alone have manifest symptoms
of HD, with twice as many additional individuals yet to manifest symptoms. Extensive efforts
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on the part of researchers, emboldened by these unfortunate
facts, identified the genetic basis of HD in the early 1990’s. Since
then, the effort to find a cure has accelerated, although to date
only one therapeutic agent has been approved for clinical use.
Physicians are therefore left to consider off-label uses of existing
therapies. Deep brain stimulation (DBS) has been used in HD
as a treatment for disabling chorea but targeted stimulation
may be a potential consideration to palliate symptoms
of HD.
Several longitudinal studies have contributed to the current
understanding of the natural history of HD (Paulsen et al.,
2008; Ross and Tabrizi, 2011; Ross et al., 2014). The mean
age of onset is 40 with an additional 20 years of life expected
after the disease manifests (Tabrizi et al., 2011). Onset is
defined with the emergence of motor symptoms. Chorea---
abrupt, random, involuntarymovements---is the hallmark of HD.
These movements often intensify before being replaced with
voluntary motor deficits. The cognitive features of HD consist
of executive dysfunction, visuospatial dysfunction, cognitive
slowing, and loss of mental flexibility. Evidence suggests that
cognitive dysfunction may parallel (or precede) the emergence
of motor deficits (Paulsen and Long, 2014). The psychiatric
manifestations vary widely, ranging from mood disturbances to
obsessional anxiety and, rarely, psychosis. Furthermore, limbic
dysfunction, in the setting of cognitive inflexibility and poor
insight, contributes to a ‘dysexecutive syndrome’, characterized
by perseveration, apathy, impulsivity and aggression. Non-
pharmacologic interventions may be helpful in early stages
but tend to become less effective as the disease progresses.
Tetrabenazine is the only FDA-approved agent for the treatment
of the chorea. Psychiatric symptoms are managed similarly to the
general population. Cognitive symptoms are typically resistant
to intervention. Biomarkers that correlate to disease stages have
not yet been defined, although promising considerations in
premanifest individuals have been identified (Paulsen et al.,
2014).
Pathogenic Mechanisms of HD
HD exhibits autosomal dominant inheritance and is equally
prevalent in men and woman. In those who inherit the mutation,
a cytosine-adenosine-guanine (CAG) repeat expansion is added
to the IT15 huntington (HTT) gene on the short arm of
chromosome 4 (Raymond et al., 2011). Affected individuals with
the mutated form have between 36 and 121 CAG repeats in
the coding region that translate into a polyglutamine expansion.
The age of onset of motor symptoms inversely correlates with
the number of repeated sequences (Ross et al., 2014). In healthy
persons, HTT encodes a protein (huntingtin) responsible for
synaptic vesicular transit and other cellular functions that when
absent leads to in utero death (Cepeda et al., 2007). For example,
wild type huntingtin contributes to the cortical production of
brain derived neurotrophic factor (BDNF) before the latter’s
downstream support of striatal neurons (Zuccato et al., 2010).
In those with the mutation, glutamine residues accumulate
and the mutant HTT protein disrupts cellular signals and
homeostasis decades before symptoms emerge. The mutation
is detectable in nervous tissue diffusely; however, the disease is
uniquely characterized by its expression in the medium spiny
neurons (MSNs) found in the caudate, putamen and cortical
pyramidal cells. The eventual death of these MSNs is the
pathological hallmark of the structural damage demonstrated in
HD (Georgiou-Karistianis et al., 2013). The precise cascade of
events that leads to neurodegeneration is still largely unknown
(Raymond et al., 2011).
MSNs account for 90% of all neurons in the striatum and
are its only output source (Murer et al., 2002). There are two
subtypes of MSNs that are differentiated by the peptides co-
expressed; the receptor subtypes and the target to which they
project. These GABAergic MSNs exert their effect via a direct or
indirect pathway. MSNs in the indirect pathway (striaopallidal,
D2 receptors) project to the external segment of the globus
pallidus (GPe) and subthalamic nucleus (Cepeda et al., 2007).
These indirect pathway neurons are the first cell population to
succumb in HD and are implicated in the hyperkinesia that
heralds the onset of the disease. MSNs in the direct pathway
(striatonigral, D1 receptors) project to the internal segment of
the globus pallidus (GPi) and the substantia nigra pars reticulatea
(SNr; Cepeda et al., 2007). Degeneration of direct pathwayMSNs,
and the resulting loss of substance P, may contribute to late stage
motor features characterized by impaired voluntary movement
(Raymond et al., 2011). This transition from hyperkinesia to
akinesia during the natural history of the disease may confound
the results of interventions aimed at arresting or controlling
chorea.
Impaired dopamine homeostasis is another consequence of
the mutation that contributes to the impaired information
processing from cortical inputs to the striatum (André
et al., 2010). Dopaminergic neurons projecting from the
substantia nigra pars compacta, and to a lesser degree the
ventral tegmental area (VTA), to the dorsal striatum regulate
glutamate sensitivity as well (dorsal circuit). Indirect pathway
MSNs express D2 receptors whereas D1 receptors are more
abundant in direct pathway MSNs. Degeneration of these
nigrostriatal dopaminergic neurons are observed in HD and
may contribute to late onset akinesia (André et al., 2010;
Raymond et al., 2011). Conversely, presynaptic hyperactivation
of the nigrostiatal pathway may elicit the characteristic chorea
of early stage disease (André et al., 2010). Agents affecting
dopamine (DA) transmission are used to modulate HD
symptoms with some effect. DA may facilitate the ‘‘upstate’’
or depolarized state that enables encoding of specific motor
tasks routed by the corticostriatal pathway (Murer et al.,
2002).
The primary inputs to theMSNs are glutamatergic projections
from the neocortex. Cortical neuron death is also observed
in HD, especially in layers III, V and VI. The cell death is
profound enough to be observed on gross pathological specimens
and predates the onset of motor symptoms. One hypothesis
is that excitotoxicity at the cortico-striatal synapses underpins
HD (Cepeda et al., 2007). This is supported by evidence that
increased release of glutamate from cortical projections, together
with reduced uptake from the synaptic cleft by glial cells and
enhanced striatal sensitivity to glutamate contributes to an
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amplified affect (Wójtowicz et al., 2013). In mouse models of
HD, down-regulation of GLT1 has been demonstrated (Liévens
et al., 2001). GLT1, a sodium-dependent glutamate transporter,
ordinarily serves to remove extracellular glutamate and limit
excitotoxicity. This down-regulation, together with NMDA-R
hypersensitivity, increases intracellular calcium and induces an
apoptotic cascade in HD.
Aspiny cholinergic, fast spiking, interneurons that co-express
parvoalbumin are the main inhibitory neurons within the
striatum (Russo et al., 2013). Theses interneurons are typically
preserved until the late stages of the disease and are at least
partly responsible for information processing and integration
in the normal striatum (Raymond et al., 2011). Although,
the death of the interneurons lags behind the MSNs, the
dystonia that is especially pronounced in early onset and
juvenile HD may be related to interneuron death (Reiner et al.,
2013).
Abnormal Electrophysiology in HD
Under normal conditions, the ventral, dorsolateral (motor)
and dorsomedial (associative) striatum are both activated
simultaneously during specific task learning (Williams and
Eskandar, 2006; Gale et al., 2014; Thorn and Graybiel, 2014).
As a behavior becomes habitual, the association between striatal
components decouples and the ventral (Gale et al., 2014) and
motor striatum emerges while the activity of the associative
striatum, now redundant, recedes (Williams and Eskandar,
2006; Thorn and Graybiel, 2014). In the ventral striatum, the
learning related facilitation of activity is thought to represent
the increased expectation of reward for the execution of specific
stimulus-motor behaviors (Gale et al., 2014). Thus, under normal
conditions, it is thought that the ventral striatum provides the
motivation to engage in reward obtaining behaviors. In HD, the
depressive and limbic symptoms may be related to motivational
changes brought on by dysfunction of striatal MSNs and/or
dopamine de-innervation (via dopamine cell loss of the SNpc
and VTA). In the dorsal striatum, once a task is learned, the
specific motor sequences or chunks are organized within the
basal ganglia as a concatenation of neuronal activity played out in
the direct and indirect pathway. Co-activation of these pathways
facilitates the desired movement by suppressing unwanted
movements (indirect) and expressing the specific motor chunk
(direct pathway) (Jin et al., 2014). Near limitless combinations
of nested oscillating frequencies are able to associate with
these specified action sequences. Normally, when an action
is queued, an assembly of neurons transitions to the upstate,
enabling the asynchronous, specified action to emerge (Stern
et al., 1998). However, in HD, the bidirectional cortico-striatal
network is no longer able to precisely orchestrate action as
nested frequencies uncouple (Miller et al., 2011). Together with
the thalamocortical network, which helps set the membrane
potential of the MSNs, the system becomes deregulated. As
redundancies in the system also dissociate, the behavior chunk
fails.
This high degree of coordination needed to facilitate a desired
movement is evident when studied on a smaller scale. In mouse
models of HD, widespread electrophysiologic dysfunction at the
neuronal level is observed. The MSNs demonstrate a depolarized
resting membrane potential. This induces hyper-excitability of
the depolarization dependent NMDA receptor in response to
glutamate. The overactive cells create an energy sink that may
lead to cellular death (Rebec et al., 2006). Similar findings are
noted in cortical pyramidal cells. As the disease progresses, the
overactive cortico-striatal pathway eventually becomes less active
and cortical synaptic inputs are lost (Cepeda et al., 2003).
Normalizing large-scale nested oscillations or stabilizing
more localized dysfunctional units in HD is challenging. To
achieve this, establishing how fundamental frequencies within
the striatum evolve throughout the course of HD will be
paramount. Recordings from the dorsal striatum in one study
of freely moving normal rats demonstrated LFPs in the 1--30 Hz
range with a relatively isolated peak at 50--55Hz (Masimore et al.,
2004). Still, LFPs in HD patients have not been well characterized
(Estrada-Sánchez and Rebec, 2013). Once known, an attempt
to tune the local frequency with electrical stimulation (ES) to
regulate function may be possible.
In HD, re-entrainment of the striatum through ES of both
the direct and indirect pathway, may repair learning deficits or
reduce the rate of loss of existing habitual circuits. ES may also
be able to partially restore the energy imbalance by reducing
the hyper-excitable state, consequently preserving cortical inputs.
Interestingly, in some animal models of HD, the cortex assumes
a hyper-excitable state only after the disease has progressed. This
finding contrasts with the observations in MSNs but may mark
an identifiable time point for intervention (Cummings et al.,
2009).
Deep Brain Stimulation for HD
There are several reports describing the use of DBS in HD when
debilitating chorea predominates in the presence of atrophy and
structural changes. We must be cautious in the interpretation of
these studies based on the heterogeneity (Table 1). The target
most often selected was GPi and DBS was primarily offered to
control medically refractory chorea in most cases; although the
progression to hypokinesia later in the disease can sometimes
complicate interventions (Reiner, 2004). Although cognition was
either not addressed or mentioned only in brief, these studies
serve as a starting point for the next generation of DBS therapies
for HD.
In one of the earliest published reports, bilateral GPi
leads were implanted in a patient with pharmacologically-
refractory HD chorea (Moro et al., 2004). 40 Hz stimulation
improved the chorea and dystonia in this patient. The
effect was enhanced at higher frequencies (130 Hz) but this
exacerbated the bradykinesia, corroborating findings in other
studies. Positron Emission Tomography (PET) studies in this
patient also demonstrated increased cerebral blood flow in
the supplementary motor area, anterior cingulate cortex and
sensorimotor cortex with ‘‘ON’’ stimulation only. It is unclear
what, if any, cognitive gains may have been facilitated by DBS.
In the wake of the success treating this initial patient, others
followed, publishing their findings after bilateral GPi DBS for HD
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TABLE 1 | Summary of published deep brain stimulation reports for HD.
Target(s) N Ages(s) at surgery Approximate disease duration CAG repeat
(years) prior to DBS (years) length(s)
Moro et al. (2004) GPi 1 43 8 -
Hebb et al. (2006) GPi 1 41 13 47
Biolsi et al. (2008) GPi 1 60 10 44
Fasano et al. (2008) GPi 1 72 17 -
Ligot et al. (2011) GPe 5 41--60 2--5 41--53
Kang et al. (2011) GPi 2 57 10 42
50 5 41
Groiss et al. (2011) GPi 1 65 - -
Spielberger et al. (2012) GPi 1 30 9 58
Cislaghi et al. (2013)* GPi 1 27 12 74
Huys et al. (2013) GPi 1 40 3 -
Velez-Lago et al. (2013) GPi 2 34 7 60
25 6 68
Gonzalez et al. (2014) GPi 7 30--78 3--8 40--50
Gruber et al. (2014) STN and GPi 1 41 9 49
Beste et al. (2014) GPe 2 57 - 42
32 53
*Westphal variant; (-) indicates data was not found or reported.
with mixed, but generally favorable, results (Hebb et al., 2006;
Spielberger et al., 2012).
Biolsi et al. described a patient with bilateral GPi DBS
implantation for chorea, which also had moderate subcortical
cognitive dysfunction at the time of surgery (Biolsi et al.,
2008). Four years later, the cognitive dysfunction remained
stable and the patient was still able to perform complicated
motor tasks. DBS in this case reduced the chorea and may
have been neuroprotective, although his disease progression
had been noted to be slow even prior to DBS. In another
case, bilateral GPi DBS was performed which demonstrated
global progressive cognitive decline on serial testing. He, like
others, developed bradykinesia after DBS that prevented stable
ambulation (Fasano et al., 2008). In two other patients who
underwent bilateral GPi, chorea was improved at 2 years
but cognitive decline continued, suggesting DBS was unable
to halt progression of cognitive dysfunction (Kang et al.,
2011).
Another report of two patients who underwent DBS of the
GPi as a palliative treatment for disabling motor symptoms
was recently published (Velez-Lago et al., 2013). In one patient,
for whom chorea was the predominate symptom, DBS reduced
a chorea subscore on the Unified HD Rating Scale. In the
second patient, DBS was offered as a treatment of generalized,
non-fixed dystonia. This failed to improve her dystonia, and
the devices were eventually turned off. Although GPi DBS is
a well-established treatment for primary generalized dystonia,
the dystonic symptoms in HD are unique and appear to
reflect the loss of direct pathway striatal neurons in advanced
disease.
In the largest published series to date, seven patients
with refractory chorea were treated with bilateral GPi DBS
between 2008 and 2010 (Gonzalez et al., 2014). Similar to
the other studies, chorea improved on average 60% at 1
year but a favorable improvement on the total motor score
was not observed (Gonzalez et al., 2014). Importantly, DBS
did not alleviate dystonia; while deactivation of stimulation
reactivated chorea, indicating that, as for other movement
disorders, the effects on motor symptoms depend on continuous
stimulation.
Gruber et al. implanted a patient using simultaneous STN
and GPi DBS in an attempt to recalibrate the direct and
indirect pathways. This strategy minimized the bradykinesia
observed following GPi stimulation alone (Gonzalez et al., 2014).
Not surprisingly, when STN was used alone, chorea was not
sustainably improved (Gruber et al., 2014).
Because of its role in error processing control, the GPe is
another potential target for DBS in patients with HD exhibiting
cognitive dysfunction. Error processing control, a measure of
negative feedback that updates a behavioral action in real
time, is believed to underlie early executive dysfunction in HD
(Smith et al., 2000). Temel et al. tested DBS of the globus
pallidus externus in a transgenic rat model of HD to evaluate
the effect on motor and cognitive function (Temel et al.,
2006). Cognitive function was measured by performance on
a choice reaction time test. Transgenic rats will prematurely
release a lever associated with a food reward compared to
controls. This indicates that transgenic rats are unable to
suppress the unwanted response. In both wild type rats and
transgenic rats, DBS improved performance on the choice
reaction time test relative to preoperative testing. Although the
number of animals tested was small, this study suggests DBS
restores unwanted response inhibition in the indirect pathway-
--a necessary precursor for executing learned behavior in the co-
activation model.
In part, based on these results, Ligot et al. proposed that
inhibitory stimulation of GPe would suppress thalamocortical
hyperactivity-induced hyperkinesia as well as influence
cognitive and behavioral symptoms (Ligot et al., 2011). To
study this effect, the investigators used PET imaging to
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FIGURE 1 | Therapeutic targets for deep brain stimulation in HD.
The scale of the response could be modulated by using different
stimulation paradigms in addition to the location of the lead(s). For
example, increasing dopaminergic activity through SNc stimulation may
improve non-specific striatal processing that governs learning. Similarly,
thalamic stimulation at low frequencies may modulate multiple nested
frequencies simultaneously to re-establish a normal frequency spectrum.
High frequency, triggered focal, pulsed stimulation of the striatum paired to
a specific task could augment learning of specific skills by boosting event
sequencing.
compare 15 control subjects with 5 HD patients implanted
with stimulation electrodes in GPe. In the resting state,
cortico-subcortical regional cerebral blood flow is reduced in
HD with the stimulator off. In keeping with the basal ganglia
thalamocortical circuit model, GPe stimulation modulated
connectivity and further reduced regional cerebral blood
flow in the basal ganglia, cortical structures and the default
mode network (Ligot et al., 2011). These findings lead to
the conclusion that stimulation of GPe may benefit patients
with HD. In a recently completed prospective pilot study,
intended to test both GPe and GPi stimulation using a
crossover design, DBS of GPe in two patients with HD
seemed to restore error processing control, although this
effect was washed out when the system was turned off
(Beste et al., 2014). Based on these studies and current
models of learning, it is our impression, that GPe DBS
warrants continued study as a potentially therapeutic target
in HD.
Deep Brain Stimulation for HD: Future
Directions
The effects of HD lead to cortical disassociation where new
behaviors and motor tasks are no longer acquired and existing
concatenations that subserve simple and complex skills are
decoupled. While the current results of DBS in HD patients may
seem disappointing at first, a great deal has been learned. Earlier
human studies are primarily aimed at evaluating safety of a novel
therapy. The current stage of knowledge seems to support that
GPi and GPe DBS may or may not improve motor symptoms
but, in general, effects of stimulation were not deleterious.
With safety largely established, new studies can be initiated
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including controlled trials. New therapies could be aimed at
realigning cortical and subcortical structures or reinforce existing
pathways, particularly when neural compensation is most
responsive (Papoutsi et al., 2014). Cognitive biomarkers that can
be detected during the prodromal stages and followed during
disease progression, such as working memory, psychomotor
speed, reaction to negative emotions, and executive functioning,
may be most promising (Dumas et al., 2013).
It is our opinion that DBS may hold promise in preserving
brain function in patients with HD to maintain independence
and reduce suffering. However, because the phenotypic
expression of HD is heterogeneous, DBS may only benefit a
select group of patients. Determining this subset is paramount
to the success of any intervention. Fortunately, recent large-
scale longitudinal studies (such as PREDICT-HD) that have
identified specific functional imaging signals indicating early
neuronal dysfunction in HD have exposed this window of
opportunity. Targeted ES, early in the course of disease may be
able to overcome limitations via several mechanisms including:
(1) regulation of dopamine homeostasis, (2) focal inhibition or
(3) activation of local brain regions, (4) task specific, triggered
closed-loop stimulation or (5) diffuse modulation of multiple
pathways with low frequency stimulation (Figure 1). Deciding
when to initiate a diseasemodifying therapy inHD is challenging.
Intervention in the prodromal stage exposes an individual to risk
when they may be able to live and work independently for many
more years. Similarly, initiating therapy after significant cell
death, a precursor to end-stage disease, may be futile. The ethical
considerations in delivering neuromodulation should therefore
be taken very seriously before such an intervention is delivered
to a desperate population (Ford and Kubu, 2006).
The question remains open on whether DBS may have any
effect in slowing disease progression in HD. To date DBS
has not demonstrated neuroprotection for motor decline in
other degenerative conditions (Lilleeng et al., 2014). We believe
HD may be unique to PD in the ability to identify gene
positive individuals prodromally and closely predict the age of
motor symptom onset, early in the course of cortico-striatal
dysfunction. Furthermore, even if unable to change the trajectory
of a terminal disease such as HD, the ability to successfully
improve functional capacity and, in turn, optimism (especially
early in the disease process), would have a substantial impact on
quality of life at an individual level, and the potential for positive
economic consequences at a societal level.
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